Get the Stockscreener App
4.83
2.77%
0.13
After Hours:
4.83
Nyxoah Sa stock is traded at $4.83, with a volume of 14,505.
It is up +2.77% in the last 24 hours and down -1.23% over the past month.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
See More
Previous Close:
$4.70
Open:
$4.7
24h Volume:
14,505
Relative Volume:
0.28
Market Cap:
$207.82M
Revenue:
$4.71M
Net Income/Loss:
$-46.77M
P/E Ratio:
-2.8764
EPS:
-1.6792
Net Cash Flow:
$-60.34M
1W Performance:
+3.87%
1M Performance:
-1.23%
6M Performance:
-37.84%
1Y Performance:
-51.06%
1-Day Range:
$4.70
$4.87
1-Week Range:
$4.45
$4.87
52-Week Range:
$4.345
$11.87
Nyxoah Sa Stock (NYXH) Company Profile
Name
Nyxoah Sa
Sector
Industry
Phone
-
Address
-
Compare NYXH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NYXH
Nyxoah Sa
|
4.83 | 202.22M | 4.71M | -46.77M | -60.34M | -1.6792 |
|
ISRG
Intuitive Surgical Inc
|
592.85 | 200.78B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
205.36 | 56.69B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
81.81 | 39.62B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
249.19 | 35.81B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
MDLN
Medline Inc
|
39.77 | 30.70B | 27.43B | 1.27B | 1.01B | 1.5829 |
Nyxoah Sa Stock (NYXH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-23 | Initiated | H.C. Wainwright | Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| Apr-21-22 | Initiated | Oppenheimer | Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Peer Perform |
| Dec-21-21 | Resumed | Cantor Fitzgerald | Overweight |
| Jul-28-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Nyxoah Sa Stock (NYXH) Latest News
Nyxoah receives Medicare reimbursement increases for Genio - MSN
Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Contrasting Azenta (NASDAQ:AZTA) and Nyxoah (NASDAQ:NYXH) - Defense World
Baird Maintains Nyxoah SA(NYXH.US) With Hold Rating, Cuts Target Price to $5.87 - 富途牛牛
Nyxoah announces commercial launch of Genio system in the Netherlands - MSN
Nyxoah launches Genio therapy in Netherlands and closes first €22.5 million tranche of convertible notes - MSN
Nyxoah price target lowered to EUR 5 from EUR 7 at Baird - MSN
Nyxoah Announces Issuance of First Tranche of Convertible Bonds - The Manila Times
Is Nyxoah SA stock positioned for digital transformationQuarterly Trade Review & Consistent Return Investment Signals - Улправда
Nyxoah Launches Genio Therapy in Netherlands and Closes First €22.5 Million Tranche of Convertible Notes - TipRanks
Earnings Recap: Is Nyxoah SA stock a good choice for value investorsJuly 2025 Highlights & Target Return Focused Picks - moha.gov.vn
Can Nyxoah SA stock deliver strong Q4 earningsQuarterly Growth Report & Smart Swing Trading Alerts - DonanımHaber
Is Nyxoah SA stock a good choice for value investorsBull Run & Free Technical Confirmation Trade Alerts - Bölüm Sonu Canavarı
Is Nyxoah SA (5YI) stock undervalued historicallyJuly 2025 Sentiment & Daily Profit Maximizing Tips - DonanımHaber
How Nyxoah SA stock performs in high volatility markets2025 Historical Comparison & Expert Curated Trade Setups - ulpravda.ru
Nyxoah Launches New OSA Therapy | Patient-Centric Breakthrough - Precedence Research
Why Nyxoah SA stock is recommended by analystsTake Profit & Step-by-Step Swing Trade Plans - Улправда
Nyxoah Launches Genio Neurostimulator System in the Netherlands - marketscreener.com
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands - FinancialContent
Nyxoah (NASDAQ:NYXH) Trading Down 2.9%Here's What Happened - MarketBeat
Nyxoah (NASDAQ:NYXH) Trading Down 2.9% – Here’s What Happened - Defense World
Nyxoah announces shareholding changes as Robert Taub surpasses 10% threshold - MSN
Critical Analysis: Nyxoah (NASDAQ:NYXH) & P3 Health Partners (NASDAQ:PIII) - Defense World
Nyxoah Announces Shareholding Changes as Robert Taub Surpasses 10% Threshold - TipRanks
How Nyxoah SA (5YI) stock compares with tech leadersWeekly Stock Analysis & Community Verified Trade Signals - Newser
Will Nyxoah SA stock outperform international peersIPO Watch & Accurate Technical Buy Alerts - Newser
Is Nyxoah SA stock a buy for dividend growthJuly 2025 Levels & Risk Controlled Daily Plans - Newser
Will Nyxoah SA (5YI) stock remain on Wall Street radar2025 Institutional Moves & Reliable Breakout Forecasts - Newser
Nyxoah (NYXH) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Publication relating to transparency notifications - marketscreener.com
Nyxoah Gains Favorable CMS Reimbursement Ruling for Genio System - MSN
Can Nyxoah SA (5YI) stock sustain institutional flowsJuly 2025 Intraday Action & Daily Chart Pattern Signals - Newser
What MACD trends signal for Nyxoah SA (5YI) stock2025 Dividend Review & Verified Entry Point Signals - Newser
Nyxoah’s Genio Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule - Sleep Review
Why The Narrative Around Nyxoah Is Shifting Amid Fresh Developments and Analyst Caution - Yahoo Finance
Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire
Nyxoah (NASDAQ: NYXH) schedules webcast fireside chat at Piper Sandler healthcare conference - Stock Titan
Nyxoah SA Stock Rises Pre-Market After CMS Raises Reimbursement For Sleep Disorder Therapy - MSN
Nyxoah S.A. (NASDAQ:NYXH) Q3 2025 Earnings Call Transcript - MSN
Nyxoah’s Genio therapy gets significant 2026 Medicare reimbursement increases under final CMS rule - MSN
01 Communique (TSXV: ONE) teams with Turnium to expand IronCAP X quantum-safe email - Stock Titan
Nyxoah’s Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule - Yahoo Finance
Nyxoah SA (NYXH) Q3 2025 Earnings Call Highlights: Strong US Launch and Strategic Expansion ... By GuruFocus - Investing.com Canada
Will Supply Chain Issues Impact Indian Toners Developers Limiteds PerformanceExit Strategy Tips & High Profit Investment Ideas - earlytimes.in
Will Nyxoah SA (5YI) stock extend growth storyCPI Data & Accurate Technical Buy Alerts - newser.com
Can Nyxoah SA stock sustain free cash flow growth2025 Key Lessons & Free Real-Time Market Sentiment Alerts - newser.com
Why Nyxoah SA (5YI) stock attracts wealthy investorsIndex Update & Consistent Growth Equity Picks - newser.com
Nyxoah (NASDAQ: NYXH) Reports 43,026,460 Voting Rights and Share Capital Update - Stock Titan
Why Nyxoah SA stock is seen as undervaluedJuly 2025 Decliners & Low Drawdown Investment Strategies - newser.com
Can Nyxoah SA stock sustain market leadershipJuly 2025 Market Mood & AI Forecasted Stock Moves - newser.com
Nyxoah Sa Stock (NYXH) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):